Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  NeoStem Inc    

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

NeoStem Inc : NeoStem Ranked the Number One Fastest Growing Company in the Tri-State Region on Deloitte’s 2013 Technology Fast 500 for the Second Year in a Row

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/13/2013 | 04:27pm CET

New York, Nov. 13, 2013 - NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced it ranked number one for the second year in a row in the Tri-State region and number eleven nationally on Deloitte's Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. NeoStem's revenues grew 17,053 percent during the period from 2008 to 2012.

Robin L. Smith, MD, MBA, Chairman and Chief Executive Officer of NeoStem, said, "We are proud to be recognized two years in a row for executing on an acquisition strategy that includes building synergistic companies well-positioned to grow in the exciting and emerging field of cell therapy. We are grateful to the Deloitte Technology Fast 500 for this recognition and look forward to continuing to distinguish NeoStem within the cellular therapy field and grow our contract and manufacturing business."

"The 2013 Deloitte Technology Fast 500 companies are exemplary cases of those spurring growth in a tough market through innovation," said Eric Openshaw, vice chairman, Deloitte LLP and U.S. technology, media and telecommunications leader. "This year's list is a who's who of companies behind the most exciting and innovative products and services in the technology space. We congratulate the Fast 500 companies and look forward to what they do next."

"The fastest growing companies in the US are drivers of constant innovation and operate with the agility to stay ahead of a quickly evolving marketplace, and software, biotech/pharma and internet companies continue to be at the forefront," added James Atwell, national managing partner of the Emerging Growth Company practice, Deloitte Services LP. "The companies excelling in these sectors have a startup mentality that allows them to be nimble and adapt quickly, which is why they consistently lead the list of fast-growing companies each year."

About Deloitte's 2013 Technology Fast 500™

Technology Fast 500, conducted by Deloitte LLP, provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies - both public and private - in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2008 to 2012.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least $50,000 USD or CD, and current-year operating revenues of at least $5 million USD or CD. Additionally, companies must be in business for a minimum of five years, and be headquartered within North America.

About NeoStem, Inc.

NeoStem, Inc. ("NeoStem" or the "Company") is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

For more information, please visit www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties.  Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's research and development and clinical evaluation efforts as well as efforts towards commercialization of cellular therapies, including with respect to AMR-001, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the Company's ability to successfully grow its contract development and manufacturing business.  The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors.  Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company's periodic filings with the SEC.  The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NEOSTEM INC
11/23 CALADRIUS BIOSCIENCES : Subsidiary, PCT, Earns FACT Re-Accreditation for its Cel..
11/22 CALADRIUS BIOSCIENCES : Subsidiary, PCT, Earns FACT Re-Accreditation for its Cel..
11/07 CALADRIUS BIOSCIENCES, INC. : Results of Operations and Financial Condition, Reg..
11/07 CALADRIUS BIOSCIENCES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
11/07 Caladrius Biosciences Reports 2016 Third Quarter Financial Results
11/02 CALADRIUS BIOSCIENCES TO HOST 2016 T : 00 pm Eastern Time
11/01 CALADRIUS BIOSCIENCES : Begins Enrollment of Second Cohort of Phase 2 Trial of C..
10/31 CALADRIUS BIOSCIENCES : Begins Enrollment of Second Cohort of Phase 2 Trial of C..
10/27 Caladrius Biosciences to Present at Upcoming November Conferences
10/19 CALADRIUS BIOSCIENCES, INC. : Regulation FD Disclosure (form 8-K)
More news
Sector news : Biotechnology & Medical Research - NEC
01:25aDJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2015 NeoStem will have a new name on June 8
2015 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
2015 NeoStem prices equity offering; dilution depresses shares
2015 Midday Gainers / Losers
2015 NeoStem misses on revenue
Advertisement
Financials ($)
Sales 2016 32,2 M
EBIT 2016 -33,3 M
Net income 2016 -35,1 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 0,95x
Capi. / Sales 2017 0,86x
Capitalization 30,6 M
More Financials
Chart NEOSTEM INC
Duration : Period :
NeoStem Inc Technical Analysis Chart | US6406504042 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 11,2 $
Spread / Average Target 199%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David J. Mazzo Chief Executive Officer & Director
Steven S. Myers Chairman
Joseph Talamo Chief Financial Officer & Senior Vice President
Douglas W. Losordo Chief Medical Officer & SVP-Regulatory Affairs
Robert A. Preti Director, Chief Technical Officer & Senior VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NEOSTEM INC-38.20%31
INCYTE CORPORATION-5.68%18 825
QUINTILES IMS HOLDINGS..11.90%17 971
CELLTRION, INC.--.--%10 097
SEATTLE GENETICS, INC.44.41%9 443
LONZA GROUP AG11.34%9 288
More Results